(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.37%) $78.77
(0.27%) $2.20
(0.18%) $2 335.30
(0.28%) $27.69
(0.20%) $966.80
(0.04%) $0.929
(0.04%) $10.83
(0.04%) $0.796
(0.02%) $91.36
-0.93% $ 1.070
Live Chart Being Loaded With Signals
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8...
Stats | |
---|---|
Dzisiejszy wolumen | 1.46M |
Średni wolumen | 798 146 |
Kapitalizacja rynkowa | 65.08M |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $0 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.686 |
ATR14 | $0.0570 (5.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-08 | Sigal Charles Elliott | Sell | 45 453 | Common Stock |
2023-09-08 | Sigal Charles Elliott | Sell | 113 636 | Stock Option (Right to Buy) |
2023-09-08 | Adams Chandra | Sell | 23 884 | Common Stock |
2023-09-08 | Adams Chandra | Sell | 50 000 | Stock Option (Right to Buy) |
2023-09-08 | Rath Henry C. | Sell | 44 971 | Common Stock |
INSIDER POWER |
---|
-73.84 |
Last 94 transactions |
Buy: 4 462 585 | Sell: 5 534 482 |
Wolumen Korelacja
Surface Oncology Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
TETC | 0.936 |
SGEN | 0.935 |
SGIIU | 0.935 |
VLAT | 0.935 |
ADAL | 0.934 |
MSDAU | 0.933 |
BRIV | 0.932 |
VMGA | 0.93 |
APXI | 0.929 |
AFAR | 0.928 |
10 Najbardziej negatywne korelacje | |
---|---|
MSEX | -0.948 |
GPRO | -0.945 |
RVSB | -0.941 |
JJSF | -0.941 |
IMBI | -0.939 |
MKTW | -0.939 |
AVXL | -0.938 |
TBLT | -0.936 |
TSBK | -0.933 |
NYMT | -0.931 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Surface Oncology Inc Korelacja - Waluta/Towar
Surface Oncology Inc Finanse
Annual | 2022 |
Przychody: | $30.00M |
Zysk brutto: | $30.00M (100.00 %) |
EPS: | $-1.170 |
FY | 2022 |
Przychody: | $30.00M |
Zysk brutto: | $30.00M (100.00 %) |
EPS: | $-1.170 |
FY | 2021 |
Przychody: | $2.69M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.735 |
FY | 2020 |
Przychody: | $126.16M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $1.670 |
Financial Reports:
No articles found.
Surface Oncology Inc
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej